𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients

✍ Scribed by F. Stocchi; L. Barbato; G. Nordera; A. Bolner; T. Caraceni

Publisher
Springer
Year
2004
Tongue
English
Weight
181 KB
Volume
111
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of standard carbidopa–levodop
Comparison of standard carbidopa–levodopa and sustained-release carbidopa–levodopa in parkinson's disease: Pharmacokinetic and quality-of-life measures
✍ Dr. Rajesh Pahwa; Kelly Lyons; Desni McGuire; Paul Silverstein; Felix Zwiebel; M 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB

## Abstract We compared clinical, pharmacokinetic, and quality‐of‐life measures in patients with Parkinson's disease (PD) who were on standard carbidopa‐levodopa (Std‐L) and after conversion to sustained‐release carbidopa‐levodopa 50/200 (L‐CR). A total of 20 PD patients with motor fluctuations par

Effect of entacapone, a COMT inhibitor,
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease
✍ V. V. Myllylä; K. A. Sotaniemi; A. Illi; K. Suominen; T. Keränen 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 563 KB

In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate vari

Pallidotomy improves motor responses and
Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease
✍ Elaine J. Skalabrin; Edward R. Laws Jr.; James P. Bennett Jr. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 781 KB

Stereotactic posteroventral pallidotomy (PVP) as a treatment for Parkinson's disease (PD) symptoms has been increasingly used in moderate-advanced disease. We examined the pharmacodynamic responses of PD patients to single oral levodopa doses and intravenous levodopa infusions before and after PVP s